SCHEMBL6907425

SCHEMBL6907425

O=c1[nH]cnc2n[nH]c(Br)c12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.54
ALDH1A1 P00352 2/20 0.47
TSHR P16473 2/20 0.39
LMNA P02545 2/20 0.39
ADORA2A P29274 1/20 0.39
SLC6A4 P31645 1/20 0.39
ADRA1A P35348 1/20 0.39
XDH P47989 1/20 0.39
RAB9A P51151 1/20 0.39
BLM P54132 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HPGD P15428 2/20 0.38
PARP1 P09874 3/20 0.36
PDPK1 O15530 2/20 0.36
CHEK1 O14757 1/20 0.36
PIM1 P11309 1/20 0.36
AKT1 P31749 1/20 0.36
FLT3 P36888 1/20 0.36
PIM3 Q86V86 1/20 0.36
CDK2 P24941 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6907428 0.73 LMNA (0.43) DYRK1AALDH1A1TSHRLMNAADORA2A
SCHEMBL8465889 0.67 ALDH1A1 (0.44) DYRK1AALDH1A1TSHRLMNAADORA2A
SCHEMBL30947487 0.66 DYRK1A (0.40) DYRK1AALDH1A1TSHRLMNAADORA2A
SCHEMBL12535705 0.65 PDPK1 (0.49) DYRK1AALDH1A1TSHRLMNAADORA2A
SCHEMBL20213686 0.65 LMNA (0.43) DYRK1AALDH1A1TSHRLMNAADORA2A
SCHEMBL2902002 0.65 TSHR (0.43) DYRK1AALDH1A1TSHRLMNAADORA2A
Hypoxanthine SCHEMBL30096461 0.65 ALDH1A1 (1.00) ALDH1A1TSHRLMNAADORA2ASLC6A4
Hypoxanthine SCHEMBL25381 0.65 ALDH1A1 (1.00) ALDH1A1TSHRLMNAADORA2ASLC6A4
Hypoxanthine SCHEMBL7037918 0.65 ALDH1A1 (1.00) ALDH1A1TSHRLMNAADORA2ASLC6A4
SCHEMBL28918223 0.63 DYRK1A (0.38) DYRK1AALDH1A1TSHRLMNAADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0961775-B1 PURINE L-NUCLEOSIDES, ANALOGS AND USES THEREOF ICN PHARMACEUTICALS (US) 2004-07-14 EP disclosed
US-6479463-B1 USED TO TREAT AN INFECTION, AN INFESTATION, A NEOPLASM, OR AN AUTOIMMUNE DISEASE OR TO MODULATE ASPECTS OF THE IMMUNE SYSTEM, INCLUDING MODULATION OF TH1 AND TH2 ICN PHARMACEUTICALS, INC. 2002-11-12 US disclosed
US-20020058635-A1 Purine L-nucleosides, analogs and uses thereof AVERETT DEVRON R (US) 2002-05-16 US disclosed
EP-0961775-A2 PURINE L-NUCLEOSIDES, ANALOGS AND USES THEREOF ICN Pharmaceuticals, Inc. (US) 1999-12-08 EP disclosed
WO-1998016184-A2 PURINE L-NUCLEOSIDES, ANALOGS AND USES THEREOF ICN PHARMACEUTICALS, INC. (US) 1998-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058635-A1 Purine L-nucleosides, analogs and uses thereof PNP, NUDT1, TYMP DYRK1A 2818/4885ALDH1A1 1668/4885TSHR 2233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.